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ess: mskov@dadlnet.dkSummary Background: Lower airway colonisation with Aspergillus fumigatus and
the complicating hypersensitivity reaction allergic bronchopulmonary aspergillosis
(ABPA) is well recognised in patients with cystic fibrosis (CF). There is a wide range in
reported prevalence of ABPA in CF. Differences in predisposing factors such as atopy
and climatic humidity, but also differences in reporting may in part explain this
observation. In the Australian population there is a high frequency of atopy and the
climate is relatively humid.
Patients and methods: Children and adolescents with CF ðn ¼ 277Þ from the
CF Clinic, Children’s Hospital at Westmead, Sydney, Australia were included in a
retrospectively conducted study of Aspergillus colonisation and ABPA (1998–2003).
Results: The prevalence of Aspergillus colonised patients increased significantly
from 7.4% in 1998 to 18.8% in 2002. No seasonal variation in initial positive Aspergillus
culture or in humidity was observed. A total of 13 patients (4.7%) were diagnosed with
ABPA over the study period, with a significant increase in prevalence from 0.3% in 1998
to 4.0% in 2002. In addition, the criteria used for reporting ABPA in the study
population were in agreement with the recently published diagnostic criteria for
ABPA in CF.
Conclusions: In spite of a high frequency of atopy and a relatively humid climate in
the Sydney area, Aspergillus colonisation and ABPA in CF patients was not
disproportionate. Moreover, criteria for reporting of ABPA in this setting was not
different from that in the Northern Hemisphere.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
ntre, Department of Pediatrics, National University Hospital, Rigshopitalet, Copenhagen,
(M. Skov).
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Colonisation with Aspergillus fumigatus (A. fu-
migatus) in the lower airways is prevalent in o5%
and up to 57% of patients with cystic fibrosis
(CF).1,2 The prevalence of patients who develop
the complicating hypersensitivity reaction allergic
bronchopulmonary aspergillosis (ABPA) ranges from
1% to 14% in various studies.3–6 Factors predisposing
to ABPA have been considered to be climate
humidity, resulting in higher Aspergillus spore
counts,6 and atopy.1,7 Differences in these factors
between populations may partly explain the wide
range in prevalence. Since diagnostic criteria for
ABPA have primarily been based upon studies
performed in patients with asthma and since
symptoms in ABPA overlap with other common
features in CF, the diagnosis of ABPA is difficult to
establish. Thus, the diagnosis and reporting of ABPA
may often rely upon a variety of diagnostic criteria.
A set of diagnostic criteria for ABPA in patients with
CF, as well as a screening program, has recently
been proposed by a CF Foundation sponsored
Consensus Conference panel.8
In an attempt to investigate some of the possible
factors responsible for differences in the reported
prevalence of ABPA, we performed a 5-year retro-
spective study of patients with CF at The Children’s
Hospital at Westmead, Sydney, Australia to assess
(a) Aspergillus colonisation and presence of ABPA in
an area with a high frequency of atopy, (b) the
influence of humidity on Aspergillus colonisation
and (c) the agreement between clinically used
ABPA criteria in a southern hemisphere centre and
the recently proposed CF Foundation Consensus
criteria for ABPA in CF.8 Data obtained in this
setting were compared to data previously reported
for the USA and Europe.9Patients and methods
Residents of the state New South Wales (NSW)
represents 33.6% of the patients in the Australasian
CF Data Registry (Australia and New Zealand).
Approximately 58% of children and adolescents with
CF in NSW attend The Children’s Hospital at
Westmead in Western Sydney. Thirty-seven of the
children attend a twice-yearly CF clinic conducted by
the hospital in Canberra, 300 km from Sydney, but
they were excluded from this study due to differ-
ences in climatic conditions (drier year round as well
as hotter in summer and colder in winter). The
remaining 277 patients attending the hospital for
their CF care in 2002 were the subjects of this study.According to the data submitted to the Austra-
lasian CF Registry by the hospital in 2000, patients
with CF have 3–5 visits per year in the centre,
and the number of sputum samples per patient
sent for microbiological culture per year is 1.14
in the age group 0–4 years and 1.9 cultures in
the age group X5 years.10 Serological screening
for ABPA is performed once-a-year, primarily
with measurement of total IgE and eosinophil
count. Patients who are suspected of having
ABPA on clinical grounds have cutaneous skin
prick to Aspergillus, precipitating antibodies to
Aspergillus and occasionally specific IgE anti-
bodies to Aspergillus measured. Within the
study period from January 1998 to April 2003
(5.25 years) a total of 109 patients (56 females/
53 males, mean age 12.2 years) had positive
Aspergillus cultures. Data pertained to these
patients were retrospectively reviewed and, where
relevant, compared with that from patients with
no Aspergillus found on culture sputum samples
ðn ¼ 168Þ:
The data for this study were obtained from a
number of sources including the electronic patient
medical and pathology record (Powerchart, Cerner
Corp; version 2002.03), the patient pulmonary
function record (Vmax Spectra, SensorMedics Corp;
version 10-1A) as well as the patient’s record in the
Australasian CF Registry. The following data were
recorded:(a) Total IgE as determined using the UniCap
system with results expressed as kIU/L with a
normal range less than 200 kIU/L.(b) Specific IgE antibodies (RAST) to Aspergillus as
measured by the CAP system according to the
manufacturers instructions (Pharmacia, Uppsa-
la, Sweden). Results were expressed as nega-
tive or positive, and positive results were
further subdivided into high and very high
levels.(c) Eosinophil count as measured by automated
electronic detection system. Results were ex-
pressed as 109/L. Eosinophilia was defined as
eosinophil counts 40.3 109/L.(d) Precipitating antibodies to Aspergillus as mea-
sured by radial immunodiffusion. Results were
expressed as positive or negative relative to
two somatic extracts, 1#: 20mg/mL and 2#:
2mg/mL and two filtrate antigens, 3#: 20mg/
mL and 4#: 2mg/mL.(e) Chest X-ray and chest CT-scan results.
(f) Lung function measured using spirometry and
expressed as a percentage of that predicted for
gender and height.11 Data from 1999 to 2003
were included.
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(skin prick tests—SPT) using commercial pre-
parations (Bayer, Leverkusen, Germany) includ-
ing controls (histamine dihydrochloride and
glycerol), Dermatophagoides pteronyssinus
(D. pteronyssinus), grass mix, rye grass,
A. fumigatus, Aspergillus mix and Alternaria
species (Alternaria sp.). A positive reaction was
regarded as a 3mm wheal to one or more of the
allergens. Some of the SPT had been performed
prior to the study period.Figure 1 Prevalence and incidence of Aspergillus colo-(h)
nisation in patients with cystic fibrosis attending the CF
Clinic, The Children’s Hospital at Westmead, Sydney,
Australia (1998–2002).Microbiological culture results—lower respira-
tory tract secretions are obtained by expec-
toration or endolaryngeal suction, and plated
on blood agar.Data on humidity in NSW were obtained from
ADAM, the Australian Commonwealth Bureau of
Meteorology’s climate archive. Data on humidity in
Denmark were obtained from the Danish Meteolo-
gical Institute, Copenhagen (2002).
Ethical approval was obtained from the
Children’s Hospital at Westmead Human Ethics
Committee.
The Kruskall–Wallis test (KW) for non-parametric
unpaired data was used to compare more than two
groups. Differences were considered significant
when the P values were less than 0.05. The values
are presented as medians (range) or means as
indicated. Changes in prevalence and incidence
were tested using multiple regression analysis.
The squared correlation coefficient (r2) is given.
The statistical analyses were performed using
StatView 4.5.Results
The number of patients decreased slightly within
the observation period from 299 in 1998 to 277 in
2002, mainly due to patients transferred to the
adult clinics at the age of 18 years and natural
variation in patient numbers. The annual number of
sputum samples cultured increased significantly
from 33 in 1998 (1.5 cultures per patient) to 104
in 2002 (2.0 per patient) (linear regression analysis,
r2 ¼ 0:994; Po0.01).
A significant increase was observed (linear
regression analysis, r2 ¼ 0:924; Po0.01) in the
prevalence of patients with positive Aspergillus
sputum cultures from 22 patients in 1998 (7.4%) to
52 patients in 2002 (18.8%) (Fig. 1). A. fumigatus
represented the majority (93%) of Aspergillus
species in the cultures. The other species identified
were A. flavus 3%, A. terreus 2%, A. niger 1%,A. nidulans 0.3%, and A. species 0.7%. The
incidence of patients with positive Aspergillus
cultures, based upon the prevalence in the first
year of the observation period, remained un-
changed (linear regression analysis, r2 ¼ 0:185;
P40.5). The number of years over which each
patient had a positive Aspergillus culture (max-
imum 6 years within the study period) was 2.0 years
(mean, range 1–6 years). The initial positive
Aspergillus culture was identified at a median age
of 9 years (range 1–18 years).Aspergillus allergy and ABPA
Aspergillus allergy characterised by increase in
total and specific anti-Aspergillus IgE antibody
responses (SPT or RAST) was found in 12 (7%) of
the patients with positive Aspergillus sputum
cultures. Thirteen patients (4.7% of the entire
study sample) were clinically diagnosed with ABPA
within the period (8 females/5 males, mean age 13
years, range 7–17). All the patients fulfilled the
recently recommended diagnostic criteria for ABPA
in CF.8 An additional two patients had ABPA
according to the paraclinical parameters, but have
not yet had clinical symptoms of ABPA. The 1-year
prevalence of ABPA increased significantly from
0.3% in 1998 to 4.0% in 2002 (linear regression
analysis: r2 ¼ 0:997; Po0.01) (Fig. 2).Seasonal variation
No seasonal variation in the incidence of the
initial positive Aspergillus culture for each patient
was observed (KW, P40.4) (Fig. 3). The mean
annual humidity in NSW was 64%. The relative
humidity ranged from 55% (SD77) in October to 70%
(SD79) in February, but no significant difference in
mean monthly humidity was observed (1998–2002)
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Figure 2 The prevalence of CF patients with ABPA
attending the CF Clinic, The Children’s Hospital at
Westmead, Sydney, Australia (1998–2002).
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Figure 3 The seasonal distribution of initial Aspergillus
colonisation in patients with CF attending the CF Clinic,
The Children’s Hospital at Westmead, Sydney, Australia.
Median value and range are given for each month.
M. Skov et al.890(KW, P40.4). The humidity in NSW did not change
over the years 1998–2002 (KW, P ¼ 0:49).Immediate cutaneous reactivity to
Aspergillus and in vitro presence of
Aspergillus-specific serum IgE antibodies
(SPT and RAST)
SPTs were performed in 88 (81%) of the patients
with positive Aspergillus cultures. Of these 88
patients, 8% were positive to D. pteronyssinus, 7%
to Alternaria sp. and 6% were positive to all
allergens in the panel. Thirty-four percent had
positive reactions to Aspergillus. In patients with a
positive SPT to Aspergillus, there was also a
positive reaction to D. pteronyssinus in 18% and in
10% to grass or rye/or both as well. Two of the 13
ABPA patients failed to have a positive SPT to
Aspergillus within the study period; 5 patients were
positive to Alternaria sp. and 3 patients to all
allergens in the panel. Additional 4 patients had
positive reaction to D. pteronyssinus. None of theABPA patients had isolated positive reaction to
grass or rye.
Specific IgE to Aspergillus (RAST) was measured
in seven of those with positive Aspergillus sputum
cultures. Two patients had a negative RAST. Five
patients, one with Aspergillus allergy and four with
ABPA, had a positive RAST; all of them had very
high levels.
Total IgE
The majority (75%) of Aspergillus-colonised pa-
tients had IgE levels o100 kIU/L, but some had
levels up to 500 kIU/L. When the patients were
further categorised as Aspergillus allergic (i.e.
without ABPA but positive to Aspergillus on SPT),
or having ABPA, a relationship with total IgE was
observed. In patients with Aspergillus allergy, IgE
levels were within the range of 100–1000 kIU/L,
except for one patient who had a level of 1466 kIU/
L. The IgE levels were above 1000 kIU/L in all
but one ABPA patients (mean 4353 kIU/L, range
861–9140 kUI/L).
Eosinophil counts
Eosinophil counts in patients with positive Asper-
gillus sputum cultures but without Aspergillus
allergy, or ABPA were generally o0.3 109/L. In
some patients, levels as high as 0.9 109/L were
occasionally seen. In patients with Aspergillus
allergy, eosinophil counts ranged up to 1.6 109/
L. The mean eosinophil count in ABPA patients
at the time of diagnosis was 1.0 109/L (range
0.1–2.6 109/L).
Precipitating antibodies to A. fumigatus
The precipitating antibodies to Aspergillus were
measured in 51 patients with positive Aspergillus
sputum cultures. Of 30 patients with positive
precipitating antibodies, 13 were diagnosed with
ABPA. The precipitating antibodies were in general
positive in all four solutions in these patients (see
Patients and methods).
Lung function and P. aeruginosa colonisation
The mean FEV1% was 84% predicted (range
27–165%) in patients with positive Aspergillus
sputum cultures and 74% (range 29–116) in ABPA
patients. The ABPA patient with an FEV1 of 29% had
a lung transplant within the study period as a
result of sequelae from chronic PA infection. The
percentage of Aspergillus colonised patients also
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patients 69%.
Chest X-rays and CT scans
In all ABPA patients, chest X-rays showed
opacities especially in the right upper and mid lobe
prior to and during acute ABPA. Nine patients had
bronchial thickening and bronchiectasis. One pa-
tient had aspergillomas and another rounded areas
of atelectasis. On a chest CT scan, one patient had
cylindrical bronchiectasis and another two had
bronchiectasis primarily in the upper right lobe.
Aspergillus culture negative CF patients
Screening of the 168 CF patients who had
negative Aspergillus cultures showed that 111
(66%) had IgE levels o100 kIU/L, 15 (9%) had IgE
levels between 100 and 200 kIU/L, 21 (12.5%)
had IgE levels between 200 and 500 kIU/L and
21 (12.5%) had IgE levels 4500 kIU/L. Three
patients with IgE levels above 500 kIU/L had
positive precipitating antibodies, and one of them
may have had an episode of ABPA previously. Two
patients with IgE levels between 100 and 500 kIU/L
had positive precipitating antibodies as well. None
of these patients were tested for IgE-Af. (RAST).Discussion
In NSW, Australia a high-atopy frequency of 32.5%
in children12 and the average humidity of 64%,
would be expected to pave the way for colonisation
with Aspergillus and development of ABPA in CF
patients. We found a prevalence of 18.8% colonisa-
tion with Aspergillus in the study population
(2002), which is lower than the recently reported
prevalence of approximately 25% from a US multi-
centre study,13 and the 42% in Copenhagen, Den-
mark.9 Atopic symptoms are present in 23% of
Danish children and adolescents.14 According to the
2000 report of the Australasian CF Data Registry
which includes 2195 patients in Australia and 311 in
New Zealand (27 centres), the prevalence of
Aspergillus colonisation was 20%. Data from Europe
and USA include children as well as adults, but were
nevertheless used for comparison since prevalences
of Aspergillus colonisation and ABPA seem to
plateau in late adolescence.9
The presently observed tendencies to humidity
changes during the year, although not significant,
combined with findings in other studies indicate
that humidity variation does not affect the inci-dence of initial Aspergillus culture.15,16 In spite of
the higher mean monthly relative humidity in
Denmark, 2002 (83%, range 78–91%) the Danish
climate is not considered to be a major contributor
to the higher prevalence of Aspergillus colonisa-
tion,9 since other North European centres with a
similar humidity report lower prevalences.5
Furthermore, it has recently been shown that
Aspergillus spore counts do not correlate with
Aspergillus-related disease.16
The increase in prevalence of Aspergillus coloni-
sation from 7.4% in 1998 to 18.8% in 2002 that
we report in this study is in accordance with the
general tendency towards increasing prevalence
over the last decades, e.g. in Denmark from 2%
in 1975 to 42% in 1995.9 In 1980, relatively high
and comparable prevalences of Aspergillus coloni-
sation of 8.6% in Sydney (a prospective study)17
and 12.5% in Copenhagen9 were found based on
studies including an average of 9.3 and 10.2
sputums per patient per year, respectively.18 These
results reflect the relationship between prevalence
and frequency of sampling. Different culturing
methods may also add to the range in various
reports. Since Aspergillus colonisation and ABPA is
rare in patientso6 years, the increase in mean and
median age of patients observed in Danish CF
population18 may also influence the increasing
prevalence. A liberal use of prophylactically in-
haled antibiotics has been suggested to increase
the risk of colonisation. Burns et al.13 found that
colonisation increased from 25% to 30% in patients
who received inhaled tobramycin. Previous studies
of colistin inhalation did not show an increase.9,19
The importance of inhaled antibiotics was not
addressed in the present study, but needs further
investigation.
The ABPA prevalence varies from 1% to 14% in
different studies.4,5,7,20–23 We found a ABPA pre-
valence of 4% in 2002. According to the Australasian
Registry (2000), the ABPA prevalence was 0.7% for
the age group 0–4 years and 4.2% for the age group
5–17 years, indicating that the results obtained for
this centre in this study are consistent with those
reported across for Australia. This prevalence is
however twice as high as the prevalence reported
from the multicentre Epidemiologic Study of Cystic
Fibrosis from USA (ESCF)4 and from the US Cystic
Fibrosis Foundation (CFF) Registry.24 However, it
has recently been estimated that the most likely
prevalence of ABPA patients in CF in USA is 8–12%.3
The prevalence of ABPA reported from the Eur-
opean Registry of Cystic Fibrosis (ERCF) is two-fold
higher than the presently observed Australian
prevalence (mean 7.8%, range: 2.1% in Sweden to
13.6% in Belgium).5
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(mean 4353 lIU/L) were found in patients with ABPA
in the present study. The reason for this remains
unclear, although a generally higher sensitivity to
allergens in the population may be suggested. The
diagnosis was supported by changes in chest X-rays
in all patients prior to the development of ABPA. As
previously suggested, eosinophil counts were of less
utility for the diagnosis of ABPA in patients with
CF,3,25 and severity of lung function as assessed by
FEV1 or chronic P. aeruginosa colonisation were not
associated with the presence of Aspergillus coloni-
sation in the present study. This is in agreement
with other studies.4,9,17 Patients with ABPA were
more likely to have positive cutaneous reactivity
to D. pteronyssinus and, as previously observed in
Danish patients,9 to the other mould Alternaria sp.,
but not to the other allergens in the panel.
Differences in screening and reporting within
centres may explain some of the variation in ABPA
prevalence. The prevalence of ABPA according to
the US CFF Registry relies on reporting from the
centres without strictly specified criteria. Criteria
are required in the ESCF and ERCF, but may be
applied to different degrees in the various centres.
From UK it has recently been reported that major
criteria for ABPA; such as IgE-Af, wheeze and cough
or total IgE4420 kIU/L were only present in
approximately 50% of the time.26 All the patients
diagnosed with ABPA in the present study fulfilled
the recently suggested criteria for ABPA in CF.8
Furthermore, annual screening of total IgE along
with a clinical suspicion of ABPA in patients 46
years was a safe way of identifying patients with CF
at risk of ABPA.
Thus, we conclude that a high background level
of atopy in a population and a humid climate do not
seem to have a major impact on the prevalence of
Aspergillus colonisation and ABPA in CF patients.
Recently suggested genetic factors such as HLA-DR
subtypes,27 MBL,28 GM haplotypes29 and CFTR3
may be more likely involved in the susceptibility
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